We are live on ! Find out more
FM

Frazier Management Portfolio holdings

AUM $1.12M
1-Year Est. Return 151.58%
This Fund
S&P 500
This Quarter Est. Return
-4.68%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$1.08B
AUM Growth
-$162M
Cap. Flow
-$69.4M
Cap. Flow %
-6.4%
Top 10 Hldgs %
77.96%
Holding
37
New
2
Increased
1
Reduced
8
Closed
3

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$21.4M
2
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$17.6M
3
AUTL
Autolus Therapeutics
AUTL
+$14.2M

Top Sells

Rank Stock Value
1
ARQT icon
Arcutis Biotherapeutics
ARQT
+$59.4M
2
TARS icon
Tarsus Pharmaceuticals
TARS
+$15.6M
3
ADVM
Adverum Biotechnologies
ADVM
+$14.2M
4
KRYS icon
Krystal Biotech
KRYS
+$7.48M
5
ACRS icon
Aclaris Therapeutics
ACRS
+$7.39M

Sector Composition

Rank Sector Weight
1 Healthcare 98.61%
2 Miscellaneous 1.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARQT icon
1
Arcutis Biotherapeutics
ARQT
$3.13B
$230M 21.23%
8,434,232
-2,108,558
-20% -$59.4M
PHAT icon
2
Phathom Pharmaceuticals
PHAT
$723M
$197M 18.19%
5,827,415
– –
PASG icon
3
Passage Bio
PASG
$13.9M
$66.3M 6.12%
250,461
– –
MIRM icon
4
Mirum Pharmaceuticals
MIRM
$6.08B
$61.7M 5.69%
3,566,912
– –
TBIO
5
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$57.4M 5.29%
2,082,789
-100,000
-5% -$1.97M
IOVA icon
6
Iovance Biotherapeutics
IOVA
$3.74B
$55.6M 5.13%
2,137,999
+825,000
+63% +$21.4M
KRYS icon
7
Krystal Biotech
KRYS
$10.6B
$53.6M 4.94%
787,876
-107,124
-12% -$7.48M
PCVX icon
8
Vaxcyte
PCVX
$9.1B
$52M 4.79%
2,309,554
– –
TARS icon
9
Tarsus Pharmaceuticals
TARS
$3.16B
$41.1M 3.79%
1,417,157
-500,000
-26% -$15.6M
TRIL
10
DELISTED
Trillium Therapeutics Inc.
TRIL
$30.3M 2.79%
3,123,107
– –
ANAB icon
11
AnaptysBio
ANAB
$1.7B
$23.3M 2.15%
899,700
– –
ALPN
12
DELISTED
Alpine Immune Sciences Inc
ALPN
$23.1M 2.13%
2,571,450
– –
SNDX icon
13
Syndax Pharmaceuticals
SNDX
$1.8B
$20.4M 1.88%
1,188,135
-246,910
-17% -$4.52M
STRO icon
14
Sutro Biopharma
STRO
$353M
$18.6M 1.72%
100,142
– –
ISEE
15
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$16.1M 1.48%
2,544,500
– –
KDNY
16
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$15.5M 1.43%
+1,100,000
New +$17.6M
AUTL
17
Autolus Therapeutics
AUTL
$628M
$15.2M 1.4%
+2,283,966
New +$14.2M
FLACU
18
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$15.1M 1.39%
1,501,000
– –
RGNX icon
19
Regenxbio
RGNX
$619M
$13.7M 1.26%
351,954
– –
MTEM
20
DELISTED
Molecular Templates, Inc.
MTEM
$10.7M 0.99%
91,603
– –
GRTS
21
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$9.41M 0.87%
1,030,878
– –
EPIX
22
DELISTED
ESSA Pharma
EPIX
$9.05M 0.83%
316,616
– –
ACRS icon
23
Aclaris Therapeutics
ACRS
$907M
$6.51M 0.6%
370,733
-325,267
-47% -$7.39M
EPZM
24
DELISTED
Epizyme, Inc
EPZM
$6.14M 0.57%
739,369
– –
APTX
25
DELISTED
Aptinyx Inc. Common Stock
APTX
$5.33M 0.49%
1,883,244
-1,306,835
-41% -$3.65M
1
2

Similar funds

ACMV
August Capital Management VI Palo Alto, California $1.39M AUM
FRCMI
First Round Capital Management III Philadelphia, Pennsylvania $418K AUM
DB
DCVC Bio Palo Alto, California $313K AUM
NAM
Newfleet Asset Management Hartford, Connecticut $2.05M AUM 27.28% 1-Year Est. Return
AP
Atlas Principals Charlotte, North Carolina $2.19M AUM 56.71% 1-Year Est. Return
ID
Inspire Developers Forest Hills, New York $4.07M AUM
CI
CMT Investments Chicago, Illinois $5M AUM 15.27% 1-Year Est. Return
DIF
Discovery Investment Fund Singapore $6.98M AUM

Frazier Management's Q2 2021 Portfolio in Review

As of Q2 2021, Frazier Management held 37 positions worth $1.08B, down 13% from $1.25B the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Frazier Management withdrew a net $69.4M in Q2 2021, closing 3 positions and reducing 8 holdings. Its most notable exit was Adverum Biotechnologies, an estimated $14.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, Frazier Management opened a new position in Chinook Therapeutics, Inc. Common Stock worth $15.5M.

  • Frazier Management's largest Q2 2021 buy was Chinook Therapeutics, Inc. Common Stock: 1,100,000 shares worth $15.5M.
  • Frazier Management added most to Iovance Biotherapeutics in Q2 2021, an estimated $21.4M increase.
  • Frazier Management's biggest Q2 2021 reduction was Arcutis Biotherapeutics, cutting an estimated $59.4M.
  • Frazier Management fully exited Adverum Biotechnologies in Q2 2021, selling an estimated $14.2M.
  • Frazier Management's ten largest holdings make up 78% of its $1.08B portfolio in Q2 2021.
  • Frazier Management opened 2 new positions and closed 3 in Q2 2021.
  • Frazier Management's portfolio value fell 13% quarter-over-quarter to $1.08B.

Based on Frazier Management's 13F filing for Q2 2021, filed 11 Aug 2021.